New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
Study finds that using DecisionDx-SCC to guide patient selection for adjuvant radiation therapy (ART), identifying patients with cutaneous squamous cell carcinoma (SCC) who can safely forgo the treatm...